A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia.

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Paliperidone (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 Feb 2012 Actual patient number changed from 1221 to 1220 as reported by ClinicalTrials.gov.
    • 14 Sep 2010 US FDA approved NDA for paliperidone for the acute and maintenance treatment of schizophrenia based data from this and other pivotal trials.
    • 06 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top